An international survey of classification and treatment choices for group D retinoblastoma

dc.contributor.authorScelfo, Christina
dc.contributor.authorFrancis, Jasmine H.
dc.contributor.authorKhetan, Vikas
dc.contributor.authorJenkins, Thomas
dc.contributor.authorMarr, Brian
dc.contributor.authorAbramson, David H.
dc.contributor.authorShields, Carol L.
dc.contributor.authorPe’er, Jacob
dc.contributor.authorMunier, Francis
dc.contributor.authorBerry, Jesse
dc.contributor.authorHarbour, J. William
dc.contributor.authorYarovoy, Andrey
dc.contributor.authorLucena, Evandro
dc.contributor.authorMurray, Timothy G.
dc.contributor.authorBhagia, Pooja
dc.contributor.authorPaysse, Evelyn
dc.contributor.authorTuncer, Samuray
dc.contributor.authorChantada, Guillermo L.
dc.contributor.authorMoll, Annette C.
dc.contributor.authorUshakova, Tatiana
dc.contributor.authorPlager, David A.
dc.contributor.authorZiyovuddin, Islamov
dc.contributor.authorLeal, Carlos A.
dc.contributor.authorMaterin, Miguel A
dc.contributor.authorJi, Xun-Da
dc.contributor.authorCursino, Jose W.
dc.contributor.authorPolania, Rodrigo
dc.contributor.authorKiratli, Hayyam
dc.contributor.authorAll-Ericsson, Charlotta
dc.contributor.authorKebudi, Rejin
dc.contributor.authorHonavar, Santosh G.
dc.contributor.authorVishnevskia-Dai, Vicktoria
dc.contributor.authorEpelman, Sidnel
dc.contributor.authorDaniels, Anthony B.
dc.contributor.authorLing, Jeanie D.
dc.contributor.authorTraore, Fousseyni
dc.contributor.authorRamirez-Ortiz, Marco A.
dc.contributor.departmentPediatrics, School of Medicineen_US
dc.date.accessioned2018-05-15T18:44:45Z
dc.date.available2018-05-15T18:44:45Z
dc.date.issued2017-06-18
dc.description.abstractAIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children's Hospital of Los Angeles (CHLA) version, 33% used the Children's Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationScelfo, C., Francis, J. H., Khetan, V., Jenkins, T., Marr, B., Abramson, D. H., … Ramirez-Ortiz, M. A. (2017). An international survey of classification and treatment choices for group D retinoblastoma. International Journal of Ophthalmology, 10(6), 961–967. http://doi.org/10.18240/ijo.2017.06.20en_US
dc.identifier.urihttps://hdl.handle.net/1805/16187
dc.language.isoen_USen_US
dc.publisherIJO Pressen_US
dc.relation.isversionof10.18240/ijo.2017.06.20en_US
dc.relation.journalInternational Journal of Ophthalmologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectEnucleationen_US
dc.subjectIntra-arterial chemotherapyen_US
dc.subjectOncologyen_US
dc.subjectOphthalmic artery chemosurgeryen_US
dc.subjectRetinaen_US
dc.subjectRetinoblastomaen_US
dc.titleAn international survey of classification and treatment choices for group D retinoblastomaen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515152/en_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijo-10-06-961.pdf
Size:
449.75 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: